BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, Izumi N. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol 2018;53:1142-50. [PMID: 29626296 DOI: 10.1007/s00535-018-1455-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Baatarkhuu O, Lee JS, Amarsanaa J, Kim DY, Ahn SH, Naranzul N, Enkhtuya D, Choijamts N, Batbayar P, Otgonbayar R, Saruul BU, Gantuul C, Gegeebadrakh B, Tuvshinbayar N, Badamsuren D, Ulzmaa G, Otgonbold J, Han KH. Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. Clin Mol Hepatol 2021;27:125-35. [PMID: 33242929 DOI: 10.3350/cmh.2020.0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Reference Citation Analysis]
3 He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:34-52. [DOI: 10.1111/apt.15598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
4 Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. Glob Health Med 2021;3:321-34. [PMID: 34782876 DOI: 10.35772/ghm.2021.01083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Masaki N, Kawasaki Y, Nozaki Y, Yanase M. Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct-acting antivirals in Japan: Evidence based on the nationwide, real-world database in Japan. Hepatol Res 2021;51:417-25. [PMID: 33217105 DOI: 10.1111/hepr.13596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2020;55:353-62. [PMID: 31768801 DOI: 10.1007/s00535-019-01645-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
7 Osawa L, Tamaki N, Kurosaki M, Kirino S, Watakabe K, Wang W, Okada M, Shimizu T, Higuchi M, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. Int J Mol Sci 2020;21:E3640. [PMID: 32455631 DOI: 10.3390/ijms21103640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine (Baltimore) 2019;98:e16254. [PMID: 31261592 DOI: 10.1097/MD.0000000000016254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Tahata Y, Sakamori R, Urabe A, Yamada R, Ohkawa K, Hiramatsu N, Hagiwara H, Oshita M, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatol Res 2020;50:1118-27. [PMID: 32678925 DOI: 10.1111/hepr.13547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. Ann Lab Med 2021;41:16-24. [PMID: 32829576 DOI: 10.3343/alm.2021.41.1.16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
11 Aimono Y, Kohyama N, Kamoshida T, Yamamoto T, Kogo M. Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy. Eur J Hosp Pharm 2021;28:e29-34. [PMID: 34728543 DOI: 10.1136/ejhpharm-2020-002215] [Reference Citation Analysis]
12 Kusakabe A, Kurosaki M, Itakura J, Joko K, Akahane T, Tsuji K, Kobashi H, Sohda T, Kimura H, Narita R, Furuta K, Izumi N. Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Hepatol Res 2019;49:1121-6. [PMID: 31209976 DOI: 10.1111/hepr.13387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
13 Maekawa S, Enomoto N. The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan. J Gastroenterol 2018;53:1168-9. [PMID: 29980847 DOI: 10.1007/s00535-018-1493-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH Open 2018;2:300-6. [PMID: 30619941 DOI: 10.1002/jgh3.12088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Nirei K, Kanda T, Masuzaki R, Mizutani T, Moriyama M. Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. Medicina (Kaunas) 2021;57:761. [PMID: 34440967 DOI: 10.3390/medicina57080761] [Reference Citation Analysis]
16 Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real‐world cohort study. Hepatol Res 2019;49:617-26. [DOI: 10.1111/hepr.13328] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
17 Ji F, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol 2019;71:473-85. [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
18 Martínez AP, García G, Ridruejo E, Culasso AC, Pérez PS, Pereson MJ, Neukam K, Flichman D, Di Lello FA. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. J Med Virol 2019;91:1970-8. [PMID: 31273794 DOI: 10.1002/jmv.25536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ohya K, Imamura M, Teraoka Y, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Mori N, Takaki S, Tsuji K, Aisaka Y, Ishitobi T, Katamura Y, Kodama H, Nabeshima Y, Masaki K, Honda Y, Moriya T, Kohno H, Kohno H, Chayama K. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res 2020;50:1234-43. [PMID: 32914512 DOI: 10.1111/hepr.13555] [Reference Citation Analysis]
20 Sharafi H, Maleki S, Alavian SM. Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank. Virus Res 2019;259:54-61. [PMID: 30401643 DOI: 10.1016/j.virusres.2018.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Tamaki N, Higuchi M, Kurosaki M, Kirino S, Osawa L, Watakabe K, Wang W, Okada M, Shimizu T, Takaura K, Takada H, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals. J Viral Hepat 2019;26:893-9. [DOI: 10.1111/jvh.13103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
22 Mashiba T, Joko K, Kurosaki M, Ochi H, Hasebe C, Akahane T, Sohda T, Tsuji K, Mitsuda A, Kimura H, Narita R, Ogawa C, Furuta K, Shigeno M, Okushin H, Ito H, Kusakabe A, Satou T, Kawanami C, Nakata R, Kobashi H, Tamada T, Ide Y, Yagisawa H, Morita A, Matsushita T, Okada K, Izumi N. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res 2019;49:1114-20. [PMID: 31077527 DOI: 10.1111/hepr.13362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Itakura J, Kurosaki M, Kakizaki S, Amano K, Nakayama N, Inoue J, Endo T, Marusawa H, Hasebe C, Joko K, Wada S, Akahane T, Koushima Y, Ogawa C, Kanto T, Mizokami M, Izumi N. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Rep 2020;2:100138. [PMID: 32817930 DOI: 10.1016/j.jhepr.2020.100138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018; 10(9): 543-548 [PMID: 30310532 DOI: 10.4254/wjh.v10.i9.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
25 Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines 2021;9:660. [PMID: 34201309 DOI: 10.3390/biomedicines9060660] [Reference Citation Analysis]
26 Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol 2022. [PMID: 35031857 DOI: 10.1007/s00535-021-01837-5] [Reference Citation Analysis]
27 Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol Res 2020;50:453-65. [PMID: 31846553 DOI: 10.1111/hepr.13474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Mizokami M, Liu LJ, Fujiyama N, Littman M, Yuan J, Sekiya T, Hedskog C, Ng LJ. Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. J Viral Hepat 2021;28:129-41. [PMID: 32869924 DOI: 10.1111/jvh.13395] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Loomba R, Izumi N. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clin Infect Dis 2021:ciaa1307. [PMID: 33544129 DOI: 10.1093/cid/ciaa1307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, Watanabe T, Yoshida O, Tokumoto Y, Mashiba T, Yokota T, Abe M, Michitaka K, Hiasa Y, Joko K. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100. [PMID: 33278003 DOI: 10.1007/s00535-020-01747-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]